opment charges were $1,037,063 compared to $678,865 during the same
period in 2007. During the six month period ended March 31, 2008, research
and development expenses were $2,066,029 compared to $1,185,023 during the
same period in 2007.
During the three month period ended March 31, 2008, general and
administrative expenses were $968,820 compared to $1,316,146 during the
same period in 2007. During the six month period ended March 31, 2008,
general and administrative expenses were $2,754,569 compared to $2,368,850
during the same period in 2007.
The Company has operations in Vienna, Virginia and Baltimore, Maryland.
CEL-SCI's other products, which are currently in pre-clinical stage, have
shown protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense.
CEL-SCI CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended
March 31,
2008 2007
REVENUE:
Grant revenue $- $17,917
Rent income - 6,805
Other income - -
Total Revenue - 24,722
EXPENSES:
Research and development, excluding
depreciation of $97,035 and
$20,832 included below 1,037,063 678,865
Depreciation and amortization 79,215 42,316
General and administrative 968,820 1,316,146
Total Expenses 2,085,098 2,037,327
LOSS F
'/>"/>
SOURCE CEL-SCI Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial2.
CEL-SCI Corporation Releases Letter to Shareholders3.
CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan4.
Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI5.
RediStat Corporation Partners With ALERT FM for Disaster-Proof Emergency Communications6.
Select Medical Corporation Announces Results for First Quarter Ended March 31, 20087.
Diagnostic Health Corporation Names Robert E. Gontarek as COO8.
AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III9.
Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 200810.
Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference11.
CRH Medical Corporation opens Center in New York